Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) – Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy

Abstract

Aim This update of the interdisciplinary S3 guideline on the Diagnosis, Therapy and Follow-up of Cervical Cancer (AWMF Registry No. 032/033OL) was published in March 2021. This updated guideline was funded by German Cancer Aid (Deutsche Krebshilfe) as part of the German Guideline Program in Oncology. The guideline was coordinated by the German Society of Gynecology and Obstetrics (Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, DGGG) and the Working Group on Gynecological Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie, AGO) of the German Cancer Society (Deutsche Krebsgesellschaft, DKG).

Method The process of updating the S3 guideline dating from 2014 was based on an appraisal of the available evidence using the criteria of evidence-based medicine, adaptations of existing evidence-based national and international guidelines or – if evidence was lacking – on a consensus of the specialists involved in compiling the update. After an initial review of the current literature was carried out according to a prescribed algorithm, several areas were identified which, in contrast to the predecessor version from September 2014, required new recommendations or statements which took account of more recently published literature and the appraisal of the new evidence.

Recommendations The short version of this guideline consists of recommendations and statements on the epidemiology, screening, diagnostic workup and therapy of patients with cervical cancer. The most important new aspects included in this updated guideline include the newly published FIGO classification of 2018, the radical open surgery approach for cervical cancers up to FIGO stage IB1, and use of the sentinel lymph node technique for tumors ≤ 2 cm. Other changes include the use of PET-CT, new options in radiotherapy (e.g., intensity-modulated radiotherapy, image-guided adaptive brachytherapy), and drug therapies to treat recurrence or metastasis.

Key words

guideline - cervical cancer - cervical intraepithelial neoplasia - therapy - follow-up

Publication History

Received: 29 September 2021
Received: 14 October 2021

Accepted: 17 October 2021

Article published online:
11 February 2022

• References/Literatur

• 1 RKI. Krebs in Deutschland für 2015/2016. 2019 Online (Stand: 28.09.2021): https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2019/krebs_in_deutschland_2019.pdf;jsessionid=E24C98E8A5A6CD3A1D73BB6A09D30A39.2_cid363?__blob=publicationFile
• 2 Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (GEKID). 2014. Online (Stand: 11.08.2019): https://atlas.gekid.de/CurrentVersion/atlas.html
• 3 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Prävention des Zervixkarzinoms, Langversion 1.1, 2020, AWMF Registernummer: 015/027OL. Online (Stand: 28.09.2021): http://www.leitlinienprogramm-onkologie.de/leitlinien/zervixkarzinom-praevention/
• 4 Evidenz- und konsensbasierte Leitlinie Impfprävention HPV-assoziierter Neoplasien – Langfassung – AWMF-Register Nr.: 082-002, 2020. Online (Stand: 28.09.2021): https://www.awmf.org/uploads/tx_szleitlinien/082-002l_S3_Impfpraevention-HPV-assoziierter-Neoplasien_2020-07_01.pdf
• 5 Bipat S, Glas AS, van der Velden J. et al. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol Oncol 2003; 91: 59-66
• 6 SIGN. SIGN: Management of Cervical Cancer. 2008 Online (Stand: 28.09.2021): https://www.sign.ac.uk/our-guidelines/management-of-cervical-cancer/
• 7 Thomeer MG, Gerestein C, Spronk S. et al. Clinical examination versus magnetic resonance imaging in the pretreatment staging of cervical carcinoma: systematic review and meta-analysis. Eur Radiol 2013; 23: 2005-2018
• 8 Choi HJ, Ju W, Myung SK. et al. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. Cancer Sci 2010; 101: 1471-1479
• 9 Gouy S, Morice P, Narducci F. et al. Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging. J Clin Oncol 2013; 31: 3026-3033
• 10 Tsai CS, Lai CH, Chang TC. et al. A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy. Int J Radiat Oncol Biol Phys 2010; 76: 477-484
• 11 Kang S, Kim SK, Chung DC. et al. Diagnostic value of (18)F-FDG PET for evaluation of paraaortic nodal metastasis in patients with cervical carcinoma: a metaanalysis. J Nucl Med 2010; 51: 360-367
• 12 Meads C, Auguste P, Davenport C. et al. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling. Health Technol Assess 2013; 17: 1-323
• 13 Ding XP, Feng L, Ma L. Diagnosis of recurrent uterine cervical cancer: PET versus PET/CT: a systematic review and meta-analysis. Arch Gynecol Obstet 2014; 290: 741-747
• 14 Xiao Y, Wei J, Zhang Y. et al. Positron emission tomography alone, positron emission tomography-computed tomography and computed tomography in diagnosing recurrent cervical carcinoma: a systematic review and meta-analysis. Arch Med Sci 2014; 10: 222-231
• 15 Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. J Womens Health (Larchmt) 2012; 21: 1031-1037
• 16 Wittekind C, Meyer H. TNM-Klassifikation maligner Tumoren. Weinheim: Viley-VCH Verlag; 2010
• 17 Obrzut B, Semczuk A, Naróg M. et al. Prognostic Parameters for Patients with Cervical Cancer FIGO Stages IA2-IIB: A Long-Term Follow-Up. Oncology 2017; 93: 106-114
• 18 Suprasert P, Srisomboon J, Charoenkwan K. et al. Twelve years experience with radical hysterectomy and pelvic lymphadenectomy in early stage cervical cancer. J Obstet Gynaecol 2010; 30: 294-298
• 19 Kasamatsu T, Onda T, Sawada M. et al. Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix. Br J Cancer 2009; 100: 1400-1405
• 20 Lee YJ, Kim DY, Lee SW. et al. A postoperative scoring system for distant recurrence in node-positive cervical cancer patients after radical hysterectomy and pelvic lymph node dissection with para-aortic lymph node sampling or dissection. Gynecol Oncol 2017; 144: 536-540
• 21 Cohen PA, Jhingran A, Oaknin A. et al. Cervical cancer. Lancet 2019; 393: 169-182
• 22 Lapuz C, Kondalsamy-Chennakesavan S, Bernshaw D. et al. Stage IB cervix cancer with nodal involvement treated with primary surgery or primary radiotherapy: Patterns of failure and outcomes in a contemporary population. J Med Imaging Radiat Oncol 2016; 60: 274-282
• 23 Horn LC, Hentschel B, Fischer U. et al. Detection of micrometastases in pelvic lymph nodes in patients with carcinoma of the cervix uteri using step sectioning: Frequency, topographic distribution and prognostic impact. Gynecol Oncol 2008; 111: 276-281
• 24 Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 1974; 44: 265-272
• 25 van de Lande J, Torrenga B, Raijmakers PGHM. et al. Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. Gynecol Oncol 2007; 106: 604-613
• 26 Ruscito I, Gasparri ML, Braicu EI. et al. Sentinel Node Mapping in Cervical and Endometrial Cancer: Indocyanine Green Versus Other Conventional Dyes – A Meta-Analysis. Ann Surg Oncol 2016; 23: 3749-3756
• 27 Frumovitz M, Plante M, Lee PS. et al. Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Lancet Oncol 2018; 19: 1394-1403
• 28 Charoenkwan K, Kietpeerakool C. Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in patients with gynaecological malignancies. Cochrane Database Syst Rev 2010; (01) CD007387
• 29 Kim HS, Sardi JE, Katsumata N. et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol 2013; 39: 115-124
• 30 Rydzewska L, Tierney J, Vale CL. et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2012; (12): CD007406
• 31 Ramirez PT, Frumovitz M, Pareja R. et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med 2018; 379: 1895-1904
• 32 Lin Y, Chen K, Lu Z. et al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis. Radiat Oncol 2018; 13: 177
• 33 Green J, Kirwan J, Tierney J. et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005; (03) CD002225
• 34 Wang N, Guan QL, Wang K. et al. Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Arch Gynecol Obstet 2011; 283: 103-108
• 35 Rosa DD, Medeiros LRF, Edelweiss MI. et al. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev 2012; (06) CD005342
• 36 Rogers L, Siu SSN, Luesley D. et al. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database Syst Rev 2012; (05) CD007583
• 37 Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 2010; (01) CD008285
• 38 Dueñas-González A, Zarbá JJ, Patel F. et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011; 29: 1678-1685
• 39 Lutgens L, van der Zee J, Pijls-Johannesma M. et al. Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma. Cochrane Database Syst Rev 2010; (01) CD006377
• 40 Harima Y, Ohguri T, Imada H. et al. A multicentre randomised clinical trial of chemoradiotherapy plus hyperthermia versus chemoradiotherapy alone in patients with locally advanced cervical cancer. Int J Hyperthermia 2016; 32: 801-808